# US 2015/0105296 A1 · Hydroxy-sphingomyelin 22:1 as a biomarker for healthy aging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105296 A1
- Document ID: US20150105296A1
- Status: Published application
- Kind: A1
- Application number: 14/491,691
- Filed: 2014-09-19
- Published: 2015-04-16
- Earliest claimed: 2012-03-22
- Assignees: Nestec S.A.
- Applicants: Nestec S.A.
- Inventors: Sebastiano Collino; Ivan Montoliu Roura; Francois-Pierre Martin; Philippe Alexandre Guy; Serge Andre Dominique Rezzi
- Web page: https://patentgrep.com/patent/US20150105296A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/6812: {Assays for specific amino acids}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2405/08: Sphingolipids
- G01N 2800/7042: Aging, e.g. cellular aging
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.

## Claims

### Claim 1

A method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders, comprising
obtaining a serum sample from a subject
determining the level of SM-OH 22:1, in the sample, and
comparing the subject's SM-OH 22:1 level to a predetermined reference value,
wherein the predetermined reference value is based on an average serum SM-OH 22:1 level in a control population, and
wherein a lower serum SM-OH 22:1 level in the sample compared to the predetermined reference value indicates an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders.

### Claim 2 (depends on 1)

The method of claim 1, further comprising
determining the level of at least one of LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, 9-oxo-HODE, PC-O 34:1, or LTE4 in the sample, and
comparing the subject's level of at least one of LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, 9-oxo-HODE, PC-O 34:1, or LTE4 to a predetermined reference value,
wherein the predetermined reference value is based on average serum LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, 9-oxo-HODE, PC-O 34:1, or LTE4 level in a control population, and
wherein a lower serum SM-OH 22:1 level in the sample and/or a lower serum LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, or 9-oxo-HODE level in the sample compared to the predetermined reference values indicate an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders, and/or
wherein elevated serum PC-O 34:1 and/or LTE4 levels in the sample compared to the predetermined reference values indicate an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders.

### Claim 3 (depends on 1)

The method of claim 1, wherein the precision of the diagnosis is increased by also assessing whether one or more of the following biomarkers PC-O 32:1, 15-HpETE, LTB4, 8,9 EpETre is increased in serum, and/or whether one or more of the following biomarkers PC-O 34:3, PC-O 36:4, PC 36:2, 11,12-DiHETre are decreased in serum, compared to a reference value previously obtained.

### Claim 4 (depends on 1)

The method of claim 1 to diagnose a lifestyle that permits healthy ageing.

### Claim 5 (depends on 1)

The method of claim 1 to diagnose longevity.

### Claim 6 (depends on 1)

The method of claim 1 to diagnose healthier gut microflora-host interactions.

### Claim 7 (depends on 6)

The method of claim 6, wherein the healthier gut microflora-host interactions are diagnosed in elderly.

### Claim 8 (depends on 1)

The method of claim 1 to diagnose a healthier lifestyle, wherein the predetermined reference values are based on serum levels obtained from the subject before a change in lifestyle.

### Claim 9 (depends on 8)

The method of claim 8, wherein the change in lifestyle is a change in the diet.

### Claim 10 (depends on 9)

The method of claim 9, wherein the change in the diet is the use of at least one nutritional product that was previously was not consumed or consumed in different amounts.

### Claim 11 (depends on 9)

The method of claim 9 to test the effectiveness of a new nutritional regimen.

### Claim 12 (depends on 1)

The method of claim 1 wherein the levels of SM-OH 22:1 and optionally the other biomarkers are determined by 1H-NMR and/or mass spectrometry in the sample and in the reference.

### Claim 13 (depends on 1)

The method of claim 1 to diagnose a healthier lifestyle, wherein the predetermined reference mean values are
2 μM for 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 32:1,
7.80 μM for 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 34:1,
1.25 ng/100 μl for 15-hydroxy-eicosatetraenoic acid (15-HpETE),
0.013 ng/100 μl serum for Leukotriene E4(LTE4),
0.020 ng/100 μl serum for Leukotriene B4(4LTB), and/or
0.070 ng/100 μl serum for 8,9-epoxyeicosatrienoic (8,9 EpETre)
16.07 μM for Hydroxy-Sphingomyelin (SM-OH) 22:1,
52.00 μM for Lysophosphatidylcholines (LPC) 18:0,
25.00 μM for Sphingomyeline (SM) 24:0,
5.07 μM for 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 34:3,
14.30 μM for 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 36:4,
1.41 μM for 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1,
10.00 μM for Phosphatidylcholine (PC) 36:2,
0.34 ng/100 μl serum for hydroxyoctadecadienoic acid (9-HODE),
0.043 ng/100 μl serum for 9-oxo-octadecadienoic acid (9-oxo-HODE), and/or
0.017 ng/100 μl serum for 11,12-epoxyeicosatrienoic acid (11,12-DiHETre).

### Claim 14

A biomarker for the diagnosis of a lifestyle that allows delaying and/or avoiding ageing chronic inflammatory disorders, wherein the biomarker is hydroxy-sphingomyelin (SM-OH) 22:1.

### Claim 15 (depends on 14)

The biomarker in accordance with claim 14, wherein the biomarker is to be detected in serum.

### Claim 16 (depends on 1)

The method of claim 1, further comprising:
obtaining a urine sample from a subject
determining the level of phenylacetylglutamine (PAG) and/or p-cresol sulphate (PCS) in the sample, and
comparing the subject's phenylacetylglutamine (PAG) and/or PCS level to a predetermined reference value,
wherein the predetermined reference value is based on an average urine PAG and/or PCS level in a control population, and wherein elevated urine PAG and/or PCS levels in the sample compared to the predetermined reference values indicate an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders.

### Claim 17

A method for diagnosing (i) a lifestyle that favors the development of ageing related chronic inflammatory disorders, (ii) a lifestyle that is likely to prevent healthy ageing, (iii) a risk for a shortened lifespan, and/or (iv) unhealthier gut microflora-host interactions, comprising
obtaining a serum sample from a subject
determining the level of SM-OH 22:1 in the sample, and
comparing the subject's SM-OH 22:1 level to a predetermined reference value,
wherein the predetermined reference value is based on an average serum SM-OH 22:1 level in a control population, and
wherein a higher serum SM-OH 22:1 level in the sample compared to the predetermined reference value indicates (i) a lifestyle that favors the development of ageing related chronic inflammatory disorders, (ii) a lifestyle that is likely to prevent healthy ageing, (iii) an increased risk for a shortened lifespan, and/or (iv) unhealthier gut microflora-host interactions.

### Claim 18 (depends on 17)

A method for (i) delaying, avoiding and/or preventing the development of ageing related chronic inflammatory disorders, (ii) promoting healthy ageing, (iii) promoting longevity, (iv) reducing a risk for a shortened lifespan, (v) promoting healthier gut microflora-host interactions, and/or (vi) preventing unhealthier gut microflora-host interactions, comprising:
(a) performing a diagnostic method as described in claim 17; and
(b) modifying a lifestyle of the subject if the subject has (i) an increased likelihood of the development of ageing related chronic inflammatory disorders, (ii) a lifestyle that is likely to prevent healthy ageing, (iii) an increased risk for a shortened lifespan, and/or (iv) unhealthier gut microflora-host interactions.

### Claim 19 (depends on 18)

The method of claim 18, wherein the modification in lifestyle in the subject comprises a change in diet.

### Claim 20 (depends on 19)

The method of claim 19, wherein the change in diet comprises administering at least one nutritional product to the subject that has an effect on healthy ageing and/or on avoiding ageing related chronic inflammatory disorders.
